Table 3.
Ongoing clinical trials with venetoclax-based combinations for older patients with AML.
| Treatment | Trial phase | Clinical.Trials.gov identifier |
|---|---|---|
| Untreated AML | ||
| Azacitidine + venetoclax versus placebo | Phase III | NCT02993523 |
| Low-dose cytarabine + venetoclax versus placebo | Phase III | NCT03069352 |
| Azacitidine + venetoclax | Phase II | NCT03466294 |
| Decitabine 10 days + venetoclax | Phase II | NCT03404193 |
| LDAC + cladribine + venetoclax and azacitidine + venetoclax | Phase II | NCT03586609 |
| Azacitidine + venetoclax + pevonedistat (NEDD8-activating enzyme) | Phase I/II | NCT03862157 |
| Venetoclax + ivosidenib ± azacitidine | Phase I/II | NCT03471260 |
| Azacitidine + venetoclax + avelumab (PD-L1 inhibitor) | Phase I/II | NCT03390296 |
| Azacitidine + venetoclax + gemtuzumab ozogamicin | Phase I/II | NCT03390296 |
| Relapsed or refractory AML | ||
| Venetoclax + dinaciclib (CDK9 inhibitor) | Phase Ib | NCT03484520 |
| Venetoclax + alvocidib (CDK9 inhibitor) | Phase Ib | NCT03441555 |
| Venetoclax + ruxolitinib (JAK2 inhibitor) | Phase I | NCT03874052 |
| Venetoclax + gilteritinib (FLT3 inhibitor) | Phase I | NCT03625505 |
| Venetoclax + quizartinib (FLT3 inhibitor) | Phase Ib/II | NCT03735875 |
| Venetoclax + AMG-176 (MCL1 inhibitor) | Phase Ib | NCT03797261 |
| Venetoclax + S64315 (MCL1 inhibitor) | Phase I | NCT03672695 |
| Venetoclax + cobimetinib (MEK inhibitor) or Venetoclax + idasanutlin (MDM2 inhibitor) | Phase Ib/II | NCT02670044 |
| Venetoclax + lintuzumab-Ac225 (anti-CD33 monoclonal antibody) | Phase I/II | NCT03867682 |
| Azacitidine + venetoclax + Lintuzumab-Ac225 | Phase I/II | NCT03932318 |
| Venetoclax + HDM201 (MDM2 inhibitor) | Phase I | NCT03940352 |
| Venetoclax + selinexor (XPO1 inhibitor) | Phase I | NCT03955783 |
AML, acute myeloid leukemia; LDAC, low-dose cytarabine.